Is FibroBiologics, Common Stock a Good Investment?
FibroBiologics, Common Investment Advice | FBLG |
- Examine FibroBiologics, Common's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research FibroBiologics, Common's leadership team and their track record. Good management can help FibroBiologics, Common navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact FibroBiologics, Common's business and its evolving consumer preferences.
- Compare FibroBiologics, Common's performance and market position to its competitors. Analyze how FibroBiologics, Common is positioned in terms of product offerings, innovation, and market share.
- Check if FibroBiologics, Common pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about FibroBiologics, Common's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in FibroBiologics, Common Stock stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if FibroBiologics, Common Stock is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine FibroBiologics, Common Stock
Researching FibroBiologics, Common's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 24.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.55. FibroBiologics, Common had not issued any dividends in recent years.
To determine if FibroBiologics, Common is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding FibroBiologics, Common's research are outlined below:
| FibroBiologics, Common generated a negative expected return over the last 90 days | |
| FibroBiologics, Common has high historical volatility and very poor performance | |
| Net Loss for the year was (16.48 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| FibroBiologics, Common generates negative cash flow from operations | |
| FibroBiologics, Common has a poor financial position based on the latest SEC disclosures | |
| About 24.0% of the company shares are held by company insiders | |
| Latest headline from thelincolnianonline.com: FibroBiologics Earns Buy Rating from Analysts at Rodman Renshaw |
FibroBiologics, Common Quarterly Accounts Payable |
|
Earnings surprises can significantly impact FibroBiologics, Common's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises FibroBiologics, Common's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-07 | 2024-06-30 | -0.09 | -0.02 | 0.07 | 77 | ||
2024-11-27 | 2024-09-30 | -0.0867 | -0.01 | 0.0767 | 88 |
FibroBiologics, Common's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 74.86 M.Market Cap |
|
FibroBiologics, Common's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.39) | (1.46) | |
| Return On Capital Employed | (3.37) | (3.20) | |
| Return On Assets | (1.39) | (1.46) | |
| Return On Equity | (13.16) | (12.50) |
Determining FibroBiologics, Common's profitability involves analyzing its financial statements and using various financial metrics to determine if FibroBiologics, Common is a good buy. For example, gross profit margin measures FibroBiologics, Common's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of FibroBiologics, Common's profitability and make more informed investment decisions.
Basic technical analysis of FibroBiologics, Stock
As of the 18th of December 2024, FibroBiologics, Common shows the Mean Deviation of 4.93, standard deviation of 6.39, and Coefficient Of Variation of (1,506). FibroBiologics, Common technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm FibroBiologics, Common standard deviation, as well as the relationship between the treynor ratio and potential upside to decide if FibroBiologics, Common is priced favorably, providing market reflects its regular price of 2.22 per share. Please also check FibroBiologics, Common Stock jensen alpha, which is currently at (0.66) to verify the company can sustain itself at a future point.FibroBiologics, Common's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific FibroBiologics, Common insiders, such as employees or executives, is commonly permitted as long as it does not rely on FibroBiologics, Common's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases FibroBiologics, Common insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
O'heeron Pete over a week ago Disposition of 100000 shares by Oheeron Pete of FibroBiologics, Common subject to Rule 16b-3 | ||
O'heeron Pete over two weeks ago Disposition of 50000 shares by Oheeron Pete of FibroBiologics, Common subject to Rule 16b-3 | ||
Niklas Victoria Ninon Olivia over six months ago FibroBiologics Common exotic insider transaction detected | ||
Cilento Richard C Jr over six months ago FibroBiologics Common exotic insider transaction detected |
Understand FibroBiologics, Common's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing FibroBiologics, Common's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.1) | |||
| Mean Deviation | 4.93 | |||
| Coefficient Of Variation | (1,506) | |||
| Standard Deviation | 6.39 | |||
| Variance | 40.77 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.66) | |||
| Total Risk Alpha | (0.94) | |||
| Treynor Ratio | (0.11) | |||
| Maximum Drawdown | 31.15 | |||
| Value At Risk | (9.73) | |||
| Potential Upside | 10.15 | |||
| Skewness | 0.3222 | |||
| Kurtosis | 0.5052 |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.1) | |||
| Mean Deviation | 4.93 | |||
| Coefficient Of Variation | (1,506) | |||
| Standard Deviation | 6.39 | |||
| Variance | 40.77 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.66) | |||
| Total Risk Alpha | (0.94) | |||
| Treynor Ratio | (0.11) | |||
| Maximum Drawdown | 31.15 | |||
| Value At Risk | (9.73) | |||
| Potential Upside | 10.15 | |||
| Skewness | 0.3222 | |||
| Kurtosis | 0.5052 |
Consider FibroBiologics, Common's intraday indicators
FibroBiologics, Common intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of FibroBiologics, Common stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
FibroBiologics, Common Corporate Filings
F4 | 9th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 12th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 29th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 21st of June 2024 Other Reports | ViewVerify |
FibroBiologics, Stock media impact
Far too much social signal, news, headlines, and media speculation about FibroBiologics, Common that are available to investors today. That information is available publicly through FibroBiologics, media outlets and privately through word of mouth or via FibroBiologics, internal channels. However, regardless of the origin, that massive amount of FibroBiologics, data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of FibroBiologics, Common news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of FibroBiologics, Common relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to FibroBiologics, Common's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive FibroBiologics, Common alpha.
FibroBiologics, Common Corporate Management
| Ruben JD | General Counsel | Profile | |
| Hamid Khoja | Chief Officer | Profile | |
| CFA CPA | Chief Officer | Profile | |
| Ruben Garcia | General Counsel | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroBiologics, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroBiologics, Common. If investors know FibroBiologics, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroBiologics, Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.55) | Return On Assets (0.66) | Return On Equity (2.68) |
The market value of FibroBiologics, Common is measured differently than its book value, which is the value of FibroBiologics, that is recorded on the company's balance sheet. Investors also form their own opinion of FibroBiologics, Common's value that differs from its market value or its book value, called intrinsic value, which is FibroBiologics, Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroBiologics, Common's market value can be influenced by many factors that don't directly affect FibroBiologics, Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between FibroBiologics, Common's value and its price, as these two are different measures arrived at by various means. Investors typically determine if FibroBiologics, Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroBiologics, Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.